Connect with us

Hi, what are you looking for?

BioTechnology

FDA Approves Genentech’s Susvimo Drug-Eluting Eye Implant

The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months while, if necessary, supplemental ranibizumab treatment can be administered to the affected eye when the Susvimo implant is in place.

FDA Approves Genentech’s Susvimo Drug-Eluting Eye Implant

Genentech announced today that it received FDA approval for its Susvimo injection for treating macular degeneration (AMD).

South San Francisco-based Genentech, a member of the Roche Group, designed its Susvimo ranibizumab injection (100 mg/mL) for intravitreal use via ocular implant for treating people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.

Formerly called Port Delivery System with ranibizumab, Susvimo is now the first and only FDA-approved treatment for wet AMD that offers as few as two treatments per year, according to a news release. In June, the FDA accepted Genentech’s Biologics License Application (BLA) for the platform.

Susvimo delivers ranibizumab continuously as an alternative to eye injections needed as often as once per month, Genentech said. The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months while, if necessary, supplemental ranibizumab treatment can be administered to the affected eye when the Susvimo implant is in place.

“Susvimo represents a major advancement in the treatment of retinal disease, and is an important new option for patients with wet AMD,” Chief of Retina Service at Wills Eye Hospital in Philadelphia Dr. Carl Regillo said in the release. “With Susvimo, my patients now have an option that can help them maintain their vision as well as anti-VEGF injections, but on a more manageable twice-yearly treatment schedule.”

Approval comes on the back of results from the Phase II Archway study primary analysis that showed wet AMD patients treated with Susvimo achieved and maintained vision gains equivalent to monthly ranibizumab injections. Only 1.6% of Susvimo patients received supplemental ranibizumab treatment before their first refill.

The implant was also well tolerated with a favorable benefit-risk profile, but it has been associated with a three-fold higher rate of endophthalmitis compared to monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. In clinical trials, 2% of patients receiving the implant experienced at least one episode of endophthalmitis.

Genentech said Susvimo will be made available in the U.S. in the coming months.

“We believe that Susvimo can help people with wet AMD preserve their vision while potentially alleviating the treatment burden associated with current standards of care,” added Genentech CMO & Head of Global Product Development Dr. Levi Garraway. “Susvimo’s approval builds on Genentech’s long-standing commitment to people living with vision-threatening conditions.”

The post FDA approves Genentech’s Susvimo drug-eluting eye implant appeared first on Drug Delivery Business.

Seen on Drug Delivery Business: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Emerging Technologies

There is no going backward, no one wants to eliminate therapeutic and catheter options, innovation drives better access and outcomes, so what is the...

Digital Health

The company offers the program as a bundle of devices, supplies and services and delivered as a 30-day subscription to eliminate upfront costs.

Digital Health

Lexington, Massachusetts-based Fractyl Health (formerly Fractyl Laboratories) can now increase the sample size of the Revitalize-1 trial (formerly Revita-T2Di trial) from 288 to 420.

BioTechnology

This robotic assisted procedure is the first intervention within a clinical study carried out by CathBot; a joint venture between Robocath and MedBot (the...

You May Also Like

Artificial Intelligence

Today & Tomorrow: Digital Solutions in HealthTech Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare...

COVID-19

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Digital Health

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.

Artificial Intelligence

Joe Mullings discusses the Microbot – Liberty robotic platform with Harel Gadot and how a new category of surgical robotics creates a new entry...